The Parexel Podcast – Details, episodes & analysis

Podcast details

Technical and general information from the podcast's RSS feed.

The Parexel Podcast

PAREXEL

Science

Frequency: 1 episode/41d. Total Eps: 54

This podcast focuses on topics relating to the global journey to create a healthier world through developing innovative new therapies for patients everywhere.

Site

RSS

Apple

Recent rankings

Latest chart positions across Apple Podcasts and Spotify rankings.

Apple Podcasts

🇺🇸 USA - lifeSciences
19/08/2026
#90
🇬🇧 Great Britain - lifeSciences
13/04/2026
#98
🇨🇦 Canada - lifeSciences
22/10/2025
#96
🇨🇦 Canada - lifeSciences
21/10/2025
#75
🇨🇦 Canada - lifeSciences
20/10/2025
#58
🇨🇦 Canada - lifeSciences
19/10/2025
#39
🇬🇧 Great Britain - lifeSciences
05/09/2025
#96
🇬🇧 Great Britain - lifeSciences
04/09/2025
#78
🇬🇧 Great Britain - lifeSciences
03/09/2025
#65
🇬🇧 Great Britain - lifeSciences
02/09/2025
#52

Spotify

No recent rankings available

Shared links between episodes and podcasts

Links found in episode descriptions and other podcasts that share them.

See all

https://jobs.parexel.com/functional-service-provider
2 shares
https://regulatory-access.parexel.com/parexels-covid-19-expert-content/covid-19-and-the-new-pragmatism
2 shares
https://www.advarra.com/
1 share

https://uk.linkedin.com/in/alexanderraines
1 share
https://www.linkedin.com/in/amy-mckee-5967174/
1 share
https://www.linkedin.com/in/heidaran/
1 share

RSS feed quality and score

Technical evaluation of the podcast's RSS feed quality and structure.

See all

RSS feed quality

To improve

Score global : 42%

Publication history

Monthly episode publishing history over the past years.

Year

Latest published episodes

Recent episodes with titles, durations, and descriptions.

See all

Podcast: Accelerated approvals – what’s next, confirmatory trials, access, and pricing

Episode 44

Monday, August 5, 2024 • Duration 12:51

Focusing on cell and gene therapies, this podcast discusses the use of accelerated approvals for fast tracking promising novel medicines through clinical development to registration.

De-risking Drug Development | Episode 3: Plan how to get to market quickly, post proof-of-concept

Episode 43

Tuesday, July 16, 2024 • Duration 39:29

De-risking Drug Development is a five-part podcast series that explores the business-critical decisions that take place at each stage of the drug development process. We know that novel therapies often don’t meet their revenue expectations, but through informed decision-making, you can minimize risk and maximize the probability of commercial success.

This is episode three, where we discuss how to accelerate development and opportunities to differentiate your product through innovative and adaptive trial design. We focus on the importance of creating evidence packages that meet both regulatory and payer requirements, and the critical role of early value story development alongside target product profile (TPP) planning.

Read moreCollapse

Advancing Precision Oncology: Expanding Patient Access to Biomarkers and Testing Capabilities Part 1

Episode 36

Thursday, April 25, 2024 • Duration 20:51

In this first episode, join our clinical development and market access experts who discuss the role of biomarker research, discovery, and patient access in advancing precision oncology to date. Biomarkers have been central to improving patient outcomes and guiding treatment guidelines in lung, breast, and blood cancers. With that backdrop, our experts discuss the role of large-scale data sets and real-world evidence in furthering precision oncology research and improving patient outcomes in more types of cancer.

Dr. Gwyn Bebb, Senior Vice President and Global Therapeutic Head of Oncology
Wyatt Gotbetter, Senior Vice President Worldwide, Access Consulting

Read moreCollapse

CAR-T boxed warnings: What comes next?

Episode 35

Wednesday, March 6, 2024 • Duration 33:57

The FDA recently asked the six marketed CAR-T therapies to add a new boxed warning item on their labels to reflect the risk of secondary T-cell cancers. This decision follows an investigation into the new safety signal from postmarketing adverse event reports and clinical trials.

In today’s episode, Fierce Pharma’s Angus Liu talks with Parexel regulatory experts Mwango Kashoki, M.D., Senior Vice President, Global Head of Regulatory Strategy, and Steve Winitsky, M.D., Vice President, Technical - Regulatory Strategy, to understand the rationale behind the FDA’s decision and to discuss its implications for CAR-T candidates and their developers down the line.

Read moreCollapse

Preparing for a Cell and Gene Future | Episode 1: Looking Back at 2023 Achievements

Episode 34

Wednesday, January 10, 2024 • Duration 17:41

This episode is the first of our new 2024 series – Preparing for a Cell and Gene Future. In this episode, we take a look back at a banner year for cell and gene therapies and what to expect in 2024 in terms of next-generation therapies and gene editing progress with Chris Learn, Senior Vice President and Head of the Cell and Gene Center of Excellence.

Read moreCollapse

Three trends impacting market access in the EU

Episode 33

Thursday, January 4, 2024 • Duration 13:23

Rare disease drug developers face three major market access challenges in the EU market today. Parexel Pricing and Market Access expert, Sangeeta Budhia, shares what they need to know to succeed.

Read moreCollapse

How can we advance fair and ethical reimbursement for patients?

Episode 32

Tuesday, November 21, 2023 • Duration 11:21

In this podcast, Parexel Vice President of Patient Engagement Rosamund Round leads a discussion on practical challenges and regulatory considerations for patient reimbursement programs in clinical trials. Elizabeth Barksdale, Director of Regulatory Affairs and Scientific Policy for LUNGevity Foundation, a non-profit lung cancer advocacy group, and Luke Gelinas, Senior IRB Chair Director for the global clinical research compliance organization Advarra, advocate for a new framework that fully reimburses patients for travel and compensates them for an additional tier of “soft” costs that will positively impact many patients’ ability to join or remain in a clinical trial, and improve health equity.

Read moreCollapse

Beyond the Binary: Navigating Gender Diversity in Clinical Research

Episode 31

Thursday, June 8, 2023 • Duration 27:13

There are an estimated 1.6 million transgender people in the U.S. alone, with about 25% identifying as nonbinary. However, based on our research for the Beyond the Binary: Navigating Gender Diversity in Clinical Research report, we found that of the 141,000+ articles published on PubMed (a database of biomedical and life sciences literature) reporting interventional clinical trial results from 2018-2022, fewer than 1% reported study participation of transgender and nonbinary patients. We then set out to determine why this patient population is not being accurately represented in clinical research.

In this episode, Parexel subject matter experts – Rosamund Round, Vice President, Patient Engagement Center; Liam Paschall, Senior Consultant, Management Development; Amy McKee, M.D., Chief Medical Officer & Global Head, Oncology Center of Excellence – discuss the barriers faced by the transgender and nonbinary communities and provide recommendations for more gender-inclusive clinical trials.

To view the Discussions on Diversity report, click here.

Read moreCollapse

Why Rare Disease Therapeutics Need Early Market Access Planning

Episode 30

Tuesday, January 3, 2023 • Duration 30:17

When developing and bringing a therapeutic for a rare disease to market, sponsors should think with the end in mind and plan for payer requirements early in protocol design. The economic and clinical value evidence required by payers for market access differs from the clinical efficacy and safety evidence demanded by regulators. Securing approval but lacking market access results in unrealized revenue and, most importantly, patients left untreated. But how do we price and how do we gain access on the promise of long-term value when we don’t have the long-term data? In this podcast by Blog Talk Radio, Sangeeta Budhia, VP and Global Head, Pricing and Market Access, and Wyatt Gotbetter, Worldwide Head, Access Consulting, of Parexel discuss early market access planning, including inclusive data collection, payer models and the impact of new regulations and innovative trial design on data collection and ongoing evidence provision.

Read moreCollapse

CROs and Their Role for Nano-rare

Episode 29

Tuesday, January 3, 2023 • Duration 27:56

In this episode on n-Lorem Foundation’s podcast series, Patient Empowerment Program, our CEO Jamie Macdonald interviews with Dr. Stanley T. Crooke, Founder, CEO and Chairman of n-Lorem Foundation. During their conversation, Jamie shares the moment he realized his desire to make a difference, Parexel’s role in clinical trials and our partnership with n-Lorem aimed to serve patients.

Read moreCollapse

The Parexel Podcast – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Spotify

Shared links between episodes and podcasts

RSS feed quality and score

Publication history

Latest published episodes

Related Shows Based on Content Similarities

Related Shows Based on Content Similarities

Apple Podcasts

Spotify

The Parexel Podcast – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Spotify

Shared links between episodes and podcasts

Other9

LinkedIn4

RSS feed quality and score

Publication history

Latest published episodes

Similar podcasts and content

Related Shows Based on Content Similarities

Related Shows Based on Content Similarities

Other9

LinkedIn4

Apple Podcasts

Spotify